Check-Cap (NASDAQ:CHEK) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of Check-Cap (NASDAQ:CHEKGet Rating) from a hold rating to a sell rating in a report issued on Monday morning, Zacks.com reports.

According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. “

Separately, Dawson James upgraded Check-Cap from a neutral rating to a buy rating in a research report on Monday, February 7th.

Shares of CHEK opened at $0.35 on Monday. The business has a 50-day simple moving average of $0.38 and a two-hundred day simple moving average of $0.60. The stock has a market cap of $33.93 million, a price-to-earnings ratio of -1.68 and a beta of 0.30. Check-Cap has a 52 week low of $0.33 and a 52 week high of $1.91.

Check-Cap (NASDAQ:CHEKGet Rating) last issued its quarterly earnings results on Thursday, April 7th. The medical research company reported ($0.06) EPS for the quarter. Equities research analysts forecast that Check-Cap will post -0.25 EPS for the current year.

Several large investors have recently added to or reduced their stakes in CHEK. Goldman Sachs Group Inc. grew its position in shares of Check-Cap by 784.5% during the third quarter. Goldman Sachs Group Inc. now owns 89,329 shares of the medical research company’s stock worth $78,000 after purchasing an additional 79,230 shares in the last quarter. UBS Group AG grew its position in shares of Check-Cap by 5,112.4% during the third quarter. UBS Group AG now owns 52,124 shares of the medical research company’s stock worth $46,000 after purchasing an additional 51,124 shares in the last quarter. Two Sigma Securities LLC purchased a new stake in shares of Check-Cap during the third quarter worth about $44,000. ARK Investment Management LLC grew its position in shares of Check-Cap by 6.8% during the fourth quarter. ARK Investment Management LLC now owns 3,257,788 shares of the medical research company’s stock worth $2,198,000 after purchasing an additional 207,260 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of Check-Cap during the fourth quarter worth about $206,000. Hedge funds and other institutional investors own 4.87% of the company’s stock.

About Check-Cap (Get Rating)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Further Reading

Get a free copy of the Zacks research report on Check-Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.